TG Therapeutics Inc TGTX:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
16.62UNCH (UNCH)
Volume
39,921
Close
16.62quote price arrow down-0.30 (-1.77%)
Volume
2,179,011
52 week range
6.46 - 33.58
Loading...
  • Open16.91
  • Day High17.12
  • Day Low16.60
  • Prev Close16.92
  • 52 Week High33.58
  • 52 Week High Date05/12/23
  • 52 Week Low6.46
  • 52 Week Low Date10/16/23

Key Stats

  • Market Cap2.569B
  • Shares Out154.54M
  • 10 Day Average Volume5.81M
  • Dividend-
  • Dividend Yield-
  • Beta2.31
  • YTD % Change-2.69

KEY STATS

  • Open16.91
  • Day High17.12
  • Day Low16.60
  • Prev Close16.92
  • 52 Week High33.58
  • 52 Week High Date05/12/23
  • 52 Week Low6.46
  • 52 Week Low Date10/16/23
  • Market Cap2.569B
  • Shares Out154.54M
  • 10 Day Average Volume5.81M
  • Dividend-
  • Dividend Yield-
  • Beta2.31
  • YTD % Change-2.69

RATIOS/PROFITABILITY

  • EPS (TTM)0.22
  • P/E (TTM)75.37
  • Fwd P/E (NTM)-313.58
  • EBITDA (TTM)48.527M
  • ROE (TTM)43.93%
  • Revenue (TTM)289.334M
  • Gross Margin (TTM)93.53%
  • Net Margin (TTM)14.24%
  • Debt To Equity (MRQ)63.29%

EVENTS

  • Earnings Date07/30/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On TG Therapeutics Inc

 

Profile

MORE
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting...
Michael Weiss J.D.
Chairman of the Board, President, Chief Executive Officer
Sean Power
Chief Financial Officer, Treasurer, Corporate Secretary
Address
3020 Carrington Mill Blvd., Suite 475
Morrisville, NC
27560-5435
United States

Top Peers

SYMBOLLASTCHG%CHG
DNLI
Denali Therapeutics Inc
18.31-0.36-1.93%
TWST
Twist Bioscience Corp
42.37-0.83-1.92%
MOR
MorphoSys AG
18.00+0.13+0.73%
IMCR
Immunocore Holdings PLC
58.95-0.90-1.50%
VCEL
Vericel Corp
48.10-0.55-1.13%